AnaptysBio, Inc.
HealthcareNASDAQ:ANAB · NASDAQ Global Select
+$1.83 today
Vol 0.39M · Avg 0.78M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-35.6%
avg -51.5%
ROIC
14.6%
avg -13.3%
ROA
-3.6%
avg -15.0%
Analysis
ROIC is currently the strongest return metric at 14.6% versus its period average of -13.3%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Daniel R. Faga | President, Chief Executive Officer & Director | $1.20M | — | 46 | $379,620.00 | 0.88% |
Paul F. Lizzul FAAD | Chief Medical Officer | $795,198.00 | — | 51 | $42,088.00 | 0.10% |
Eric J. Loumeau | Chief Legal Officer | $722,002.00 | — | 63 | $35,000.00 | 0.08% |
Christopher Murphy | Chief Financial Officer | $673,635.00 | — | 42 | $25,765.00 | 0.06% |
Dennis Mulroy | Chief Financial Officer | $673,635.00 | — | 71 | $21,852.00 | 0.05% |
Monique Da Silva | Senior Vice President of Corporate Affairs | — | — | — | — | — |
Priya Raina | Senior Vice President of Clinical Operations | — | — | — | — | — |
Martin Dahl | Senior Vice President of Research | — | — | — | — | — |
John Kwon | Vice President of GI Clinical Development | — | — | — | $16,510.00 | 0.04% |
David McKeon | Senior Vice President & Controller | — | — | 54 | — | — |
Benjamin Stone | Chief Business Officer | — | — | 35 | — | — |
Cailin Sibley FACR | Senior Vice President of Translational Medicine | — | — | — | — | — |
Beth Mueller | Senior Vice President of Human Resources | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
48
$10.58M
Net Sentiment
$10.58M
Net selling
Most Active
Faga Daniel
13 transactions
1–10 of 48
Analysis
Insiders reported 0 buys worth $0.00 and 48 sells worth $10.58M over the last 12 months. That adds up to net selling of $10.58M. Faga Daniel was the most active insider with 13 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | -14.2% | +34.5% (13yr)3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Recent growth has been strongest in Revenue at -14.2% over three years. Forward estimates point to Revenue at +34.5% (13yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Dianthus Therapeutics, Inc.
NASDAQ:DNTH
$3.43B
Kodiak Sciences Inc.
NASDAQ:KOD
$1.80B
Taysha Gene Therapies, Inc.
NASDAQ:TSHA
$1.64B
Mind Medicine (MindMed) Inc.
MNMD
$1.56B
Nurix Therapeutics, Inc.
NASDAQ:NRIX
$1.47B
UroGen Pharma Ltd.
NASDAQ:URGN
$1.45B
Xencor, Inc.
NASDAQ:XNCR
$914.17M
Phathom Pharmaceuticals, Inc.
NASDAQ:PHAT
$827.07M
Oculis Holding AG
NASDAQ:OCS
$634.01M
BridgeBio Oncology Therapeutics Inc.
NASDAQ:BBOT
$620.83M
Who manages ANAB?
AnaptysBio, Inc. (ANAB) lists 13 active executives. The top listed executive is Eric J. Loumeau, Chief Legal Officer.
Are ANAB insiders buying or selling?
Recent insider activity shows net selling of $8.66M.
Explore More
Continue the stock analysis
Jump to another research area for this company.